We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App





Randox Highlights Cutting-Edge Diagnostic Products and Solutions

By LabMedica International staff writers
Posted on 23 Jul 2023
Print article
Image: The world’s first Xylazine ELISA is available on the Evidence MultiSTAT analyzer (Photo courtesy of Randox)
Image: The world’s first Xylazine ELISA is available on the Evidence MultiSTAT analyzer (Photo courtesy of Randox)

Randox Laboratories (Crumlin, UK) is exhibiting its cutting-edge diagnostic products and solutions at 2023 AACC, while also highlighting its groundbreaking technologies.

As a provider of high-quality diagnostic solutions, Randox offers a wide range of products and services, including quality control, molecular diagnostics, third-party reagents, point of care, and clinical chemistry analyzers. With an extensive product range offering expansive third-party quality controls and calibrators, inter-laboratory data management, external quality assessments, and calibration verification. Randox’s new Acusera Quality Controls for 2022/2023 highlighted at the show include Active B12, Anti Mullerian Hormone (AMH), Brain Natriuretic Peptide (BNP) Control, Bone Markers (Serum) Control, Pre-eclampsia Control, Serum Indices Control, Ultra-Low PSA Control, Xanthochromia Control.

At AACC 2023, Randox is also showcasing its recently launched and the world’s first Xylazine ELISA. Xylazine, which is an analgesic drug primarily used within the veterinary industry as a tranquilizer, has not been approved for human use but has been linked to the USA’s illicit drug supply in recent years. While the prevalence of Xylazine is showing no sign of decreasing, Randox Toxicology continues to lead in new test development within the ever-changing drugs of abuse market. The company’s newly-established test for xylazine is the first immunoassay test in the world for this drug of abuse and is available on the Evidence MultiSTAT analyzer. Evidence MultiSTAT is designed to work across a variety of matrices including blood, and oral fluid, and simultaneously screens for up to 29 drugs of abuse from a single sample in less than 31 minutes.

In recent years, Randox has been expanding its Randox Health testing – bringing preventative healthcare directly to the public. Specializing in ‘Pre-disease’ highly sensitive biomarkers in the blood are measured before an individual start to feel sick and before regular blood tests would show illness. After making the service available throughout the UK and Ireland via its innovative mobile health clinic, Randox is now unveiling Randox Health Labs located in Santa Monica, California at AACC 2023. Randox’s extensive test menu offers over 150 analytes, allowing access some of the most specialized tests available in the market today.

Related Links:
Randox Laboratories 

Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
New
Gold Member
Chagas Disease Test
CHAGAS Cassette
New
Parasite Suspension for QC
Cryptosporidium Species Parasite Suspension
New
Anti-Annexin V IgG/IgM Assay
Anti-Annexin V IgG/IgM ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: Umbilical cord blood biomarkers may improve preterm infant care (Photo courtesy of Shutterstock)

Umbilical Cord Blood Test Could Identify Preterm Infants at Risk for Medical Complications

Advancements in medical technology and neonatology have significantly improved the care of prematurely born infants. However, these infants still face heightened risks for medical complications, such as... Read more

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Microbiology

view channel
Image: The Cytovale System isolates, images, and analyzes cells (Photo courtesy of Cytovale)

Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application

Sepsis is the leading cause of death and the most expensive condition treated in U.S. hospitals. The risk of death from sepsis increases by up to 8% for each hour that treatment is delayed, making early... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.